Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nanoparticles: potential biomarker harvesters.

David H Geho1, Clinton D Jones, Emanuel F Petricoin

  • 1Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA. dgeho@gmu.edu

Current Opinion in Chemical Biology
|January 18, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Clinical Models: MEKiAUTO.

JCO precision oncology·2026
Same author

CD70 drives cSCC growth by linking DNA damage response, inflammation, and tumor-stromal signaling.

Cell death & disease·2026
Same author

Laser capture microdissection.

Nature reviews. Methods primers·2026
Same author

Immunoproteomic insights into inflammatory diseases of the critically endangered black rhinoceros (Diceros bicornis).

Scientific reports·2026
Same author

Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer.

NPJ precision oncology·2026
Same author

Pan-cancer multi-omic ERBB2-HER2 characterization using next-generation sequencing and quantitative proteomics.

NPJ precision oncology·2026
Same journal

Function through shape: An overview of DNA G-quadruplexes in transcriptional regulation.

Current opinion in chemical biology·2026
Same journal

Advances in tools and technologies for multiplexed bioluminescence imaging.

Current opinion in chemical biology·2026
Same journal

High-resolution molecular mapping by expansion-coupled label-free and multimodal imaging.

Current opinion in chemical biology·2026
Same journal

Recent advances in glycoconjugate-based therapeutics.

Current opinion in chemical biology·2026
Same journal

Towards better red emitters for bioimaging: Innovations in rhodamine and cyanine chemistry.

Current opinion in chemical biology·2026
Same journal

Chemigenetic fluorescent biosensors in biological imaging - New trends and advances.

Current opinion in chemical biology·2026
See all related articles

Nanoparticles can harvest low molecular weight proteins from blood for early cancer diagnosis. This underutilized nanotechnology offers a promising platform for biomarker discovery and disease detection.

Area of Science:

  • Biomedical Engineering
  • Proteomics
  • Nanotechnology

Background:

  • The low molecular weight proteomic fraction of blood contains valuable information for disease diagnosis.
  • Current diagnostic methods have limitations in detecting diseases like cancer at early stages.

Purpose of the Study:

  • To explore the potential of nanoparticle technology for biomarker harvesting.
  • To develop platforms for early disease diagnosis using blood proteomic data.

Main Methods:

  • Utilizing the physicochemical properties of nanoparticles, such as high surface area.
  • Engineering nanoparticle surfaces for selective binding of specific biomarkers.
  • Employing high-sensitivity proteomic tests for biomarker analysis.

Related Experiment Videos

Main Results:

  • Nanoparticles offer a malleable platform for creating effective biomarker harvesting systems.
  • Biomarker harvesting using nanoparticles is an emerging area with significant growth potential.

Conclusions:

  • Nanoparticle-based biomarker harvesting represents an underutilized but promising application of nanotechnology.
  • This approach could significantly advance early disease diagnosis, particularly for cancers.